Medical Science Liaison (North Central Plains)
ArcellxFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Candidates should possess strong scientific oncology acumen, including knowledge of therapeutic landscapes, NCCN guidelines, clinical trial data, oncology cooperative groups, and NCI/NCCN cancer centers. They must exemplify intellectual curiosity, adaptability to change, teamwork, strong communication, results-orientation, decision-making skills, and clinical/scientific expertise. A strong business acumen with working knowledge of drug development processes across research, development, clinical operations, biostatistics, regulatory, and commercial functions is also required. Approximately 50-60% travel is expected.
The Medical Science Liaison will engage in clinically meaningful scientific discussions with thought leaders in gynecological oncology and other malignancies to enhance their knowledge of Corcept and cortisol modulation in oncology. They will educate healthcare professionals on disease states where cortisol modulation may play a role, provide scientific exchange on Corcept's data and development plans, and develop strong relationships with thought leaders, patient advocacy organizations, and oncology associations. Responsibilities include capturing, analyzing, and communicating insights from the medical and scientific community to inform company decisions, supporting company-sponsored clinical trials, investigator-initiated studies, scientific communications, publications, education, advisory boards, and congresses. Maintaining high standards of scientific, clinical, and technical expertise in relevant therapeutic areas and demonstrating teamwork and collaboration within Medical Affairs and cross-functionally are also key duties.
Develops cortisol modulators for medical conditions
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.